Mylan’s India Shopping Spree Is Aimed At Doubling Global Manufacturing Capacity
This article was originally published in PharmAsia News
Executive Summary
With two manufacturing units under its belt in the past few months, Mylan may not be done acquiring assets in India.
You may also be interested in...
Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned
MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.